Investigational medications for treatment of patients with Alzheimer disease

Journal of the American Osteopathic Association

Volumn 110, Issue 9 SUPPL. 8, 2010, Pages

  Potter, Pamela E ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIMEBON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; NEW DRUG; NICOTINIC RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE V INHIBITOR; SECRETASE; TAU PROTEIN; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ALZHEIMER DISEASE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; REVIEW;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHOLINERGIC AGENTS; DRUGS, INVESTIGATIONAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULIN G; INDOLES; NICOTINIC ANTAGONISTS; PHOSPHODIESTERASE 5 INHIBITORS; RECEPTORS, TUMOR NECROSIS FACTOR; TAU PROTEINS;

EID: 78651395271     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J. 1978;2 (6150):1457-1459.
2. Dournaud P, Delaere P, Hauw JJ, Epelbaum J. Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer's disease. Neurobiol Aging.1995;16 (5):817-823.
3. Winblad B, Engedal K, Soininen H, et al; Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57(3):489-495.
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease [review]. Cochrane Database Syst Rev. January 25, 2006;(1):CD005593.
5. Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease [review]. Int J Geriatr Psychiatry. 2006;21(1):17-28.
6. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis [review]. Clin Interv Aging. 2008;3(2):211-225.
7. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia [review]. Cochrane Database Syst Rev. April 19, 2006;(2):CD003154.
8. Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials [published online ahead of print May 10, 2007]. Dement Geriatr Cogn Disord. 2007;24(1):20-27.
9. Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease [published online ahead of print July 4, 2007]. Dement Geriatr Cogn Disord. 2007;24(2):138-145.
10. Fisher A. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease modifying agents for Alzheimer's disease. Neurotherapeutics. 2008;5(3):433-442.
11. Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease-an update [review]. Curr Alzheimer Res. 2007;4(5):577-580.
12. Levey AI. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc Natl Acad Sci USA. 1996;93(24):13541-13546.
13. Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 2000;48(6):913-918.
14. Wolf BA, Wertkin AM, Jolly YC, et al. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J Biol Chem. 1995;270(9):4916-4922.
15. Haring R, Fisher A, Marciano D, et al. Mitogen activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion. J Neurochem. 1998;71(5):2094-2103.
16. Beach TG, Walker D, Sue L, et al. Immunotoxin lesion of the cholinergic nucleus baslis causes A deposition: towards a physiologic animal model of Alzheimer's disease. Curr Med Chem. 2003;3:233-243.
17. Beach TG, Walker DG, Potter PE, Sue LI, Fisher A. Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. Brain Res. 2001;905(1-2):220-223.
18. Caccamo A, Oddo S, Billings LM, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49(5): 671-682.
19. Hock C, Maddalena A, Raschig A, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid. 2003;10(1):1-6.
20. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol. 2003;54(2):235-238.
21. Davis AA, Fritz JJ, Wess J, Lah JJ, Levey AI. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J Neurosci. 2010;30(12):4190-4196.
22. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in alzheimer disease. Arch Neurol. 1997;54(4):465-473.
23. Eglen RM. Muscarinic receptors and gastrointestinal tract smooth muscle function. Life Sci. 2001;68(22-23):2573-2578.
24. Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165(8):1033-1039.
25. Fang L, Jumpertz S, Zhang Y, et al. Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors. J Med Chem. 2010;53(5):2094-2103.
26. Fisher A, Brandeis R, Bar-Ner RH, et al. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci. 2002;19(1-2):145-153.
27. Heinrich JN, Butera JA, Carrick T, et al. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009;605(1-3):53-56.
28. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov. 2009;8(1):41-54.
29. Davis CN, Bradley SR, Schiffer HH, et al. Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands. BMC Pharmacol. 2009;9:14.
30. Thomas RL, Mistry R, Langmead CJ, Wood MD, Challiss RA. G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. J Pharmacol Exp Ther. 2008;327(2):365-374.
31. Avlani VA, Langmead CJ, Guida E, et al. Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor. Mol Pharmacol. 2010;78(1):94-104.
32. Bradley SR, Lameh J, Ohrmund L, et al. AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model [published online ahead of print October 14, 2009]. Neuropharmacology. 2010;58(2):365-373.
33. Langmead CJ, Austin NE, Branch CL, et al. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharmacol. 2008;154(5):1104-1115.
34. Jones CK, Brady AE, Davis AA, et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci. 2008;28(41):10422-10433.
35. Wittmann M, Guangping X, Michelle P, et al. In vivo pharmacodynamic effects of BQCA, a novel selective allosteric M1 receptor modulator. Alzheimer Dement. 2008;4(suppl 1):T770.
36. Ferrari-DiLeo G, Mash DC, Flynn DD. Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease. Mol Chem Neuropathol. 1995;24(1):69-91.
37. Flynn DD, Weinstein DA, Mash DC. Loss of high affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann Neurol. 1991;29(3):256-262.
38. Flynn DD, Ferrari-DiLeo G, Levey AI, Mash DC. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. Life Sci. 1995;56(11-12):869-876.
39. Tsang SW, Lai MK, Kirvell S, et al. Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol Aging. 2006;27(9):1216-1223.
40. Newhouse PA, Sunderland T, Tariot PN, et al. The effects of acute scopolamine in geriatric depression. Arch Gen Psychiatry. 1988;45(10):906-912.
41. Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry. 1989;154:797-800.
42. Baker JD, Lenz RA, Locke C, et al. ABT-089, a neuronal nicotinic receptor partial agonist, reverses scopolamine-induced cognitive deficits in healthy normal subjects. Alzheimer Dement.2009;5(4 suppl 1):P325-P325.
43. Lenz RA, Berry SM, Pritchett YI, et al. Novel investigation of a neuronal nicotinic receptor partial agonist in the treatment of Alzheimer's disease. Paper presented at: 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; March 24-27, 2010; Geneva, Switzerland. P100.
44. Bitner RS, Bunnelle WH, Anderson DJ, et al. Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci. 2007;27(39):10578-10587.
45. Mudo G, Belluardo N, Fuxe K. Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm. 2007;114(1):135-147.
46. Leiser SC, Bowlby MR, Comery TA, Dunlop J. A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther. 2009;122(3):302-311.
47. D'Andrea MR, Nagele RG. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr Pharm Des. 2006;12(6):677-684.
48. Srivareerat M, Tran TT, Salim S, Aleisa AM, Alkadhi KA. Chronic nicotine restores normal Abeta levels and prevents short-term memory and E-LTP impairment in Abeta rat model of Alzheimer's disease [published online ahead of print May 20, 2009]. Neurobiol Aging.
49. Bitner RS, Nikkel AL, Markosyan S, Otte S, Puttfarcken P, Gopalakrishnan M. Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo. Brain Res. 2009;1265:65-74.
50. Bitner RS, Bunnelle WH, Decker MW, et al. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's Disease [published online ahead of print May 26 2010]. J Pharmacol Exp Ther. 2010;334(3):875-886.
51. Othman AA, Lenz RA, Zhang J, Li J, Awni WM, Dutta S. Single and multiple-dose pharmacokinetics, safety and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers [published online ahead of print June 14, 2010]. J Clin Pharmacol.
52. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010;9(7):702-716.
53. Hilt D, Safirstein B, Hassman D, et al. EVP-6124 Safety, tolerability, and cognitive effects of a novel a7 nicotinic receptor agonist in Alzheimer's disease patients on stable donepezil or rivastigmine therapy. EnVivo Pharmaceuticals Web site; 2009. http://www.envivopharma.com/library/user_files/Hilt_etal_A7_ICAD2009.pdf. Accessed September 17, 2010.
54. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173-177.
55. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408(6815):979-982.
56. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408(6815):982-985.
57. Hock C, Konietzko U, Papassotiropoulos A, et al. Generation of antibodies specific for [beta]-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 2002;8(11):1270-1275.
58. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46-54.
59. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004;14(1):11-20.
60. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9(4):448-452.
61. Bouche D, Donald J, Love S, Neal JW, Holmes C, Nicoll J. A 42 immunization reduces both tau and A deposits in Alzheimer's disease. Alzheimer Dement. 2010;6(4 suppl 1):S144-S144.
62. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553-1562.
63. Winblad BG, Minthon L, Floesser A, et al. Results of the first-in-man study with the active Abeta immunotherapy CAD106 in Alzheimer patients. Alzheimer Dement. 2009;5(4 suppl 1):P113-P114.
64. Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W. Development of AFFI-TOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing. J Nutr Health Aging. 2009;13(3):264-267.
65. Okura Y, Miyakoshi A, Kohyama K, Park IK, Staufenbiel M, Matsumoto Y. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long term effects and safety. Proc Natl Acad Sci USA. 2006;103(25):9619-9624.
66. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363-372.
67. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73(24):2061-2070.
68. Blennow K, Zetterberg H, Wei J, Liu E, Black R,Grundman M. Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease. Alzheimer Dement. 2010;6(4 suppl 1):S134-S135.
69. Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin Biol Ther. 2010;10(7):1121-1130.
70. DeMattos RB, Racke MM, Gelfanova V, et al. Identification, characterization, and comparison of amino-terminally truncated A 42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment. Alzheimer Dement. 2009;5(4 suppl 1):P156-P157.
71. Seubert P, Barbour R, Khan K, et al. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis. 2008;5(2):65-71.
72. Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol. 2010;33(2):67-73.
73. Nicholas T, Knebel W, Gastonguay MR, et al. Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer's disease. Alzheimer Dement. 2009;5(4 suppl 1):P253-P253.
74. Zhao Q, Landen J, Burstein AH, et al. Pharmacokinetics and pharmacodynamics of ponezumab (PF-04360365) following a single-dose intravenous infusion in patients with mild to moderate Alzheimer's disease. Alzheimer Dement. 2010;6(4 suppl 1):S143-S143.
75. Wood KM, McCush F, Conboy JJ, et al. IP/MS analysis of human CSF Abeta following a single dose of the C-terminal anti-Abeta antibody ponezumab (PF-04360365) to Alzheimer patients. Alzheimer Dement. 2010;6(4 suppl 1):S311-S311.
76. Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother. 2009;9(5):661-679.
77. Tomita T, Iwatsubo T. gamma-secretase as a therapeutic target for treatment of Alzheimer's disease. Curr Pharm Des. 2006;12(6):661-670.
78. Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2009;10(10):1657-1664.
79. Bateman RJ, Siemers ER, Mawuenyega KG, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66(1):48-54.
80. Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of Phase III clinical trials [press release]. Indianapolis, IN: Eli Lilly and Co; August 17, 2010. http://newsroom.lilly.com/releasedetail.cfm?releaseid=499794. Accessed September 18, 2010.
81. Jacobsen S, Comery T, Kreft A, et al. GSI-953 is a potent APP-selective gamma-secretase inhibitor for the treatment of Alzheimer's disease. Alzheimer Dement. 2009;5(4 suppl 1):P139-P139.
82. Martone RL, Zhou H, Atchison K, et al. Begace-stat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther. 2009;331(2):598-608.
83. Ereshefsky L, Jhee SS, Yen M, Moran SV. The role for CSF dynabridging studies in developing new therapies for Alzheimer's disease. Alzheimer Dement. 2009;5(4 suppl 1):P414-P415.
84. Soares H, Raha N, Sikpi M, et al. Abeta variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Abeta in healthy volunteers. Alzheimer Dement. 2009;5(4 suppl 1):P252-P253.
85. Marcade M, Bourdin J, Loiseau N, et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem. 2008;106(1):392-404.
86. Desire L, Marcade M, Peillon H, Drouin D, Sol O. Clinical trials of EHT 0202, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. Alzheimer Dement. 2009;5(4 suppl 1):P255.
87. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled Phase III study. Dement Geriatr Cogn Disord. 2010;30(2):131-146.
88. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics. 2008;5(3):481-489.
89. Hayden KM, Zandi PP, Khachaturian AS, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache County Study. Neurology. 2007;69(3):275-282.
90. Rozzini R, Ferrucci L, Losonczy K, Havlik RJ, Guralnik JM. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc. 1996;44(9):1025-1029.
91. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology. 2004;23(4):159-169.
92. Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337-351.
93. Sastre M, Gentleman SM. NSAIDs: how they work and their prospects as therapeutics in Alzheimer's disease. Front Aging Neurosci. 2010;2:20.
94. ADAPT Research Group. Cognitive function over time in the Alzheimer's disease anti-inflammatory prevention trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65(7):896-905.
95. ADAPT Research Group. Alzheimer's Disease Anti-Inflammatory Prevention Trial: Design, methods, and baseline results. Alzheimer Dement. 2009;5(2):93-104.
96. Pasqualetti P, Bonomini C, Dal Forno G, et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clin Exp Res. 2009;21(2):102-110.
97. Breitner JC, Haneuse SJ, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009;72(22):1899-1905.
98. Chandra V, Pandav R, Dodge HH, et al. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology. 2001;57(6):985-989.
99. Shaji S, Bose S, Verghese A. Prevalence of dementia in an urban population in Kerala, India. Br J Psychiatry. 2005;186:136-140.
100. Subramanian S, Sandhyarani B, Shree AN, et al. Lower levels of cerebrospinal fluid amyloid (A) in non-demented Indian controls [published online ahead of print September 15, 2006]. Neurosci Lett. 2006;407(2):121-123.
101. Kandimalla RJ, Prabhakar S, Binukumar BK, et al. Cerebrospinal fluid profile of amyloid beta42 (Abeta42), hTau and ubiquitin in North Indian Alzheimer's disease patients [published online ahead of print July 3, 2010]. Neurosci Lett.
102. Zhang C, Browne A, Child D, Tanzi RE. Curcumin decreases amyloid beta-peptide levels by attenuating the maturation of amyloid-beta precursor protein [published online ahead of print July 9, 2010]. J Biol Chem. 2010;285(37):28472-28480.
103. Qin XY, Cheng Y, Yu LC. Potential protection of curcumin against intracellular amyloid beta induced toxicity in cultured rat prefrontal cortical neurons. Neurosci Lett. 2010;480(1):21-24.
104. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21(21):8370-8377.
105. Hamaguchi T, Ono K, Yamada M. Curcumin and Alzheimer's Disease [published online ahead of print April 12, 2010.] CNS Neurosci Ther.
106. Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent dimebon as a novel neuro-protector and a cognition enhancer. Ann NY Acad Sci. 2001;939:425-435.
107. Matsuoka Y, Gray AJ, Hirata-Fukae C, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci. 2007;31(2):165-170.
108. Matsuoka Y, Jouroukhin Y, Gray AJ, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008;325(1):146-153.
109. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001;20(1-2):27-39.
110. Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem. 2002;83(6):1529-1533.
111. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 2003;423 (6938):435-439.
112. Nakashima H, Ishihara T, Yokota O, et al. Effects of alpha-tocopherol on an animal model of tauopathies. Free Radic Biol Med. 2004;37(2):176-186.
113. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102(19):6990-6995.
114. Salins P, Shawesh S, He Y, et al. Lovastatin protects human neurons against Abeta-induced toxicity and causes activation of beta-catenin-TCF/LEF signaling. Neurosci Lett. 2007;412(3):211-216.
115. Luna-Medina R, Cortes-Canteli M, Sanchez Galiano S, et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurode-generation under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci. 2007;27(21):5766-5776.
116. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27(34):9115-9129.
117. Staff RT, Ahearn TS, Murray AD, Bentham P, Seng KM, Wischik C. P4-347: tau aggregation inhibitor (TAI) therapy with rember(TM) arrests the trajectory of rCBF decline in brain regions affected by Tau pathology in mild and moderate Alzheimer's disease (AD). Alzheimer Dement. 2008;4(4 suppl 1):T775-T775.
118. Medina DX, Caccamo A, Oddo S. Methylene blue reduces Abeta levels and rescues early cognitive deficit by increasing proteasome activity [published online ahead of print July 27, 2010]. Brain Pathol.
119. Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent dimebon as a novel neuro-protector and a cognition enhancer. Ann NY Acad Sci. 2001;939:425-435.
120. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372(9634):207-215.
121. Miller G. Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer's drug. Science. 2010;327(5971):1309.
122. Perry RT, Collins JS, Wiener H, Acton R, Go RCP. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging. 2001;22(6):873-883.
123. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J. 1999;13(1):63-68.
124. Medeiros R, Prediger RD, Passos GF, et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci. 2007;27(20):5394-5404.
125. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed. 2006;8(2):25.
126. Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol. 2008;8:27.
127. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation. 2008;5:2.
128. Puzzo D, Staniszewski A, Deng SX, et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J Neurosci. 2009;29(25):8075-8086.
129. Colton CA, Wilcock DM, Wink DA, Davis J, Van Nostrand WE, Vitek MP. The effects of NOS2 gene deletion on mice expressing mutated human AβPP. J Alzheimer Dis. 2008;15(4):571-587.
130. Beeri MS, Schmeidler J, Silverman JM, et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology. 2008;71(10):750-757.
131. Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. Ann Epidemiol. 2003;13(5):369-376.
132. Holscher C, Li L. New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer's disease? Neurobiol Aging. 2010;31(9):1495-1502.
133. Gold M, Alderton C, Zvartau-Hind M, et al. Effects of rosiglitazone as monotherapy in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease. Alzheimer Dement. 2009;5(4): P86.
134. Sparks DL, Hunsaker JC III, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging. 1990;11(6): 601-607.
135. Brian MA, Emma RF, Huw D. Cholesterol upregulates production of A 1-40 and 1-42 in transfected cells. Neurobiol Aging. 2000;21:254.
136. Austen BM, Sidera C, Liu C, Frears E. The role of intracellular cholesterol on the processing of the beta-amyloid precursor protein. J Nutr Health Aging. 2003;7(1):31-36.
137. Feldman HH, Doody RS, Kivipelto M, et al; LEADe Investigators. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe [published online ahead of print March 3, 2010]. Neurology. 2010;74(12):956-964.
138. Sparks DL, Kryscio RJ, Connor DJ, et al. Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. Neurodegener Dis. 2010;7(1-3):183-186.
139. Robles A. Pharmacological treatment of Alzheimer's disease: is it progressing adequately? Open Neurol J. 2009;3:27-44.
140. Chong ZZ, Li F, Maiese K. Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better? Curr Neurovasc Res. 2005;2(1):55-72.
141. De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67(8):949-956.